Literature DB >> 21057629

A STEP forward in neural function and degeneration.

Matthew L Baum1, Pradeep Kurup, Jian Xu, Paul J Lombroso.   

Abstract

STriatal-Enriched Phosphatase (STEP) is a brain-specific protein tyrosine phosphatase that plays a role in synaptic plasticity and has recently been implicated in neurodegenerative disease. STEP opposes the development of synaptic strengthening by dephosphorylating and inactivating key signaling proteins that include the MAP kinases ERK1/2 and p38, as well as the tyrosine kinase Fyn. STEP also dephosphorylates the GluR2 subunit of the AMPAR and the NR2B subunit of the NMDAR, which leads to internalization of the NR1/NR2B and GluR1/GluR2 receptors. STEP levels and activity are regulated through phosphorylation, local translation, ubiquitination and degradation and proteolytic cleavage. Here we review recent progress in understanding the normal regulation of STEP and how this regulation is disrupted in Alzheimer's disease, in which abnormally increased STEP levels and activity contribute to the cognitive deficits.

Entities:  

Keywords:  Alzheimer's disease; STEP; glutamate receptors; proteasome; tyrosine phosphatase; ubiquitination

Year:  2010        PMID: 21057629      PMCID: PMC2974069          DOI: 10.4161/cib.3.5.12692

Source DB:  PubMed          Journal:  Commun Integr Biol        ISSN: 1942-0889


  22 in total

1.  Internalization of ionotropic glutamate receptors in response to mGluR activation.

Authors:  E M Snyder; B D Philpot; K M Huber; X Dong; J R Fallon; M F Bear
Journal:  Nat Neurosci       Date:  2001-11       Impact factor: 24.884

Review 2.  The fragile X syndrome: exploring its molecular basis and seeking a treatment.

Authors:  Barbara Bardoni; Laetitia Davidovic; Mounia Bensaid; Edouard W Khandjian
Journal:  Expert Rev Mol Med       Date:  2006-04-21       Impact factor: 5.600

3.  Regulation of NMDA receptor trafficking and function by striatal-enriched tyrosine phosphatase (STEP).

Authors:  Steven P Braithwaite; Michael Adkisson; John Leung; Adrian Nava; Brett Masterson; Roman Urfer; Donna Oksenberg; Karoly Nikolich
Journal:  Eur J Neurosci       Date:  2006-06       Impact factor: 3.386

4.  Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking.

Authors:  Penelope J Hallett; Robert Spoelgen; Bradley T Hyman; David G Standaert; Anthone W Dunah
Journal:  J Neurosci       Date:  2006-04-26       Impact factor: 6.167

Review 5.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide.

Authors:  Christian Haass; Dennis J Selkoe
Journal:  Nat Rev Mol Cell Biol       Date:  2007-02       Impact factor: 94.444

6.  Regulation of NMDA receptor trafficking by amyloid-beta.

Authors:  Eric M Snyder; Yi Nong; Claudia G Almeida; Surojit Paul; Timothy Moran; Eun Young Choi; Angus C Nairn; Michael W Salter; Paul J Lombroso; Gunnar K Gouras; Paul Greengard
Journal:  Nat Neurosci       Date:  2005-07-17       Impact factor: 24.884

7.  The role of STEP in Alzheimer's disease.

Authors:  Pradeep Kurup; Yongfang Zhang; Deepa V Venkitaramani; Jian Xu; Paul J Lombroso
Journal:  Channels (Austin)       Date:  2010-09-06       Impact factor: 2.581

8.  Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP.

Authors:  Jian Xu; Pradeep Kurup; Yongfang Zhang; Susan M Goebel-Goody; Peter H Wu; Ammar H Hawasli; Matthew L Baum; James A Bibb; Paul J Lombroso
Journal:  J Neurosci       Date:  2009-07-22       Impact factor: 6.167

9.  Co-activation of p38 mitogen-activated protein kinase and protein tyrosine phosphatase underlies metabotropic glutamate receptor-dependent long-term depression.

Authors:  Peter R Moult; Sônia A L Corrêa; Graham L Collingridge; Stephen M Fitzjohn; Zafar I Bashir
Journal:  J Physiol       Date:  2008-03-20       Impact factor: 5.182

10.  Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32.

Authors:  Anthone W Dunah; Ana C Sirianni; Allen A Fienberg; Elena Bastia; Michael A Schwarzschild; David G Standaert
Journal:  Mol Pharmacol       Date:  2004-01       Impact factor: 4.436

View more
  6 in total

Review 1.  Striatal-enriched protein tyrosine phosphatase in Alzheimer's disease.

Authors:  Jian Xu; Pradeep Kurup; Angus C Nairn; Paul J Lombroso
Journal:  Adv Pharmacol       Date:  2012

2.  Molecular mechanism of ERK dephosphorylation by striatal-enriched protein tyrosine phosphatase.

Authors:  Rong Li; Di-Dong Xie; Jun-Hong Dong; Hui Li; Kang-Shuai Li; Jing Su; Lai-Zhong Chen; Yun-Fei Xu; Hong-Mei Wang; Zheng Gong; Guo-Ying Cui; Xiao Yu; Kai Wang; Wei Yao; Tao Xin; Min-Yong Li; Kun-Hong Xiao; Xiao-Fei An; Yuqing Huo; Zhi-Gang Xu; Jin-Peng Sun; Qi Pang
Journal:  J Neurochem       Date:  2013-10-31       Impact factor: 5.372

3.  Role of Src Family Kinases in BDNF-Mediated Suppression of Cocaine-Seeking and Prevention of Cocaine-Induced ERK, GluN2A, and GluN2B Dephosphorylation in the Prelimbic Cortex.

Authors:  Sarah M Barry; Jacqueline F McGinty
Journal:  Neuropsychopharmacology       Date:  2017-06-06       Impact factor: 7.853

4.  Striatal-enriched protein-tyrosine phosphatase (STEP) regulates Pyk2 kinase activity.

Authors:  Jian Xu; Pradeep Kurup; Jason A Bartos; Tommaso Patriarchi; Johannes W Hell; Paul J Lombroso
Journal:  J Biol Chem       Date:  2012-04-27       Impact factor: 5.157

Review 5.  Protein tyrosine phosphatases: structure, function, and implication in human disease.

Authors:  Lutz Tautz; David A Critton; Stefan Grotegut
Journal:  Methods Mol Biol       Date:  2013

6.  What is the new target inhibiting the progression of Alzheimer's disease.

Authors:  Lin Zhang; Jing Yang; Yunpeng Cao
Journal:  Neural Regen Res       Date:  2013-07-25       Impact factor: 5.135

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.